Samsung Bio to expand its wheelhouse in $1.8B buy for peptide API maker

Samsung Biologics offers $1.8B for Swiss CDMO PolyPeptide, expanding beyond biologics into peptide APIs and the booming GLP-1 manufacturing market.

lunedì 20 luglio 2026 New tab

77 words~1 min read

July 20, 2026 12:18 PM EDT

Samsung Biologics is set to branch into peptide ingredient manufacturing with plans to buy Swiss CDMO PolyPeptide for $1.8 billion in …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Think we're worth reading - tell Google.

Samsung Bio to expand its wheelhouse in $1.8B buy for peptide API maker — Warptech Lab News